{
    "organizations": [],
    "uuid": "e9017881af5882f2002415ccad9727de0b2eb411",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cimzia-is-the-first-therapy-to-dem/brief-cimzia-is-the-first-therapy-to-demonstrate-positive-results-in-a-52-week-placebo-controlled-non-radiographic-axial-spondyloarthritis-study-idUSFWN1SN10A",
    "ord_in_thread": 0,
    "title": "BRIEF-Cimzia Is The First Therapy To Demonstrate Positive Results In A 52-Week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Ucb SA:\n* CIMZIAÂ® (CERTOLIZUMAB PEGOL) IS THE FIRST THERAPY TO DEMONSTRATE POSITIVE RESULTS IN A 52-WEEK, PLACEBO CONTROLLED NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STUDY\n* UCB SA - STUDY MET PRIMARY OBJECTIVE AND ALSO MET A KEY SECONDARY OBJECTIVE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T04:12:00.000+03:00",
    "crawled": "2018-05-17T14:24:53.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "ucb",
        "sa",
        "certolizumab",
        "pegol",
        "first",
        "therapy",
        "demonstrate",
        "positive",
        "result",
        "placebo",
        "controlled",
        "axial",
        "spondyloarthritis",
        "study",
        "ucb",
        "sa",
        "study",
        "met",
        "primary",
        "objective",
        "also",
        "met",
        "key",
        "secondary",
        "objective",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}